Renal Cell Carcinoma: Risk Stratification and Evolving Treatment Landscape

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma treatment in a dose-escalation trial.

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.